| Best Of BioLaw 1997-2007
|
 |
| ABSTRACTS |
|
|
|
| Volume Index |
|
Click on  to order articles
You need the Adobe Acrobat Reader in order to view the PDF files you purchase. The reader is free and you can get it by clicking on the icon to the right. 
|
|
|
|
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
|
|
Editorial Note
Robin JR Blatt and Steven H. Holtzman
|
|
|
Frank Baldino, Jr., Ph.D. | Chairman & Chief Executive Officer, Cephalon
|
|
Johsua Boger | Founder, President & Chief Executive Officer, Vertex
|
|
Alexis Borisy, A.M. | Founder, President & Chief Executive Officer, CombinatoRx, Inc.
|
|
Deborah Dunsire, MD | President and Chief Executive Officer, Millennium Pharmaceuticals, Inc.
|
|
Steven H. Holtzman | Founder, President and Chief Executive Officer, Infinity Pharmaceuticals
|
|
John Maraganore, Ph.D. | President & Chief Executive Officer, Alnylam Pharmaceuticals
|
|
Hollings C. Renton | Chairman, President and Chief Executive Officer, Onyx
|
|
George A. Scangos, PhD | President and Chief Executive Officer, Exelixis
|
|
Henri A. Termeer | Chairman, President and Chief Executive Officer, Genzyme Corporation
|
|
Topics of the Times: Selected JB&B Editorials
|
|
Sustaining Innovation and Growth in the Global Arena
Mike Ruettgers
|
|
Bringing Biotechnology Health Innovations to Patients Requires a Stronger FDA
James C. Greenwood
|
|
The Biopharmaceutical Industry in Massachusetts-The Triple Helix in Action
Ashley J. Stevens
|
|
Biotech Licensing from Universities: A Maturing of Perspective
Lita Nelsen
|
|
|
State Pension Funds as a Source of Capital for Investing in Economic Growth: The Massachusetts Model
Timothy Cahill
|
|
|
Marine Bioprospecting and Sustainable Regional Development Policies
Harlyn O. Halvorson and Fernando Quezada
|
|
|
New Technologies for Ancient Diseases
Carl B. Feldbaum
|
|
|
Making the World Safe for Biotech Patents
Bruce A. Lehman
|
|
|
Preserving Our Digital Heritage: The Stakes Are High
Mike Ruettgers
|
|
|
The Wake-Up Call of Corporate Governance
Stuart N. Brotman
|
|
|
Cartography, History, Genomes and Intellectual Property
Juan Enriquez
|
|
|
Bioterrorism: A Challenge We Cannot Decline to Meet
Carl B. Feldbaum
|
|
|
Perspectives from the Street: Life after Enron in the World of Biotech
Stelios Papadopoulos
|
|
|
Restoring Public Trust In Gene Therapy
Senator Edward M. Kennedy
|
|
|
Special Challenges in Applying Genomics to Population Health
Gilbert S. Omenn
|
|
|
New and Daunting Responsibilities for Judges: "Doing Science" in the 21st Century
The Hon. Justice Andre M. Davis
|
|
|
In Pursuit of Patents: 21st Century Challenges
Robin JR Blatt
|
|
|
Priorities for the Century of the Life Sciences
Senator Edward M. Kennedy
|
|
|
Banking Biological Collections
Robin JR Blatt
|
|
Click to buy
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
Editorial Note
Robin JR Blatt and Steven H. Holtzman
|
Abstract:
The life sciences sector is constantly undergoing transformation with the convergence of science, technology, law, business and policy and integration of these disciplines which impact the local and global society. These trends create novel opportunities as well as challenges for individuals, nations and populations. In this 10th Anniversary Special Edition of The Journal of BIOLaw & Business, we have selected the top 2007 JB&B CEO "Leading Lights"-CEOs who are world renown for staying ahead of the curve, interpreting the larger policy issues and challenges and translating them into strategic action plans for their respective companies. Each of the thought leaders interviewed serves to monitor the pulse of change, providing the executive foresight and strength to adapt their organizations and chart a new course that is responsive to the prevailing environment.
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
Frank Baldino, Jr., Ph.D. | Chairman & Chief Executive Officer, Cephalon
|
Abstract:
No Abstract
3 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
JOHSUA BOGER | Founder, President & Chief Executive Officer, Vertex Pharmaceuticals
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
Alexis Borisy, A.M. | Founder, President & Chief Executive Officer, CombinatoRx, Inc.
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
Deborah Dunsire, MD | President and Chief Executive Officer, Millennium Pharmaceuticals, Inc.
|
Abstract:
No Abstract
3 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
Steven H. Holtzman | Founder, President and Chief Executive Officer, Infinity Pharmaceuticals
|
Abstract:
No Abstract
3 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
John Maraganore, Ph.D. | President & Chief Executive Officer, Alnylam Pharmaceuticals
|
Abstract:
No Abstract
3 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
Hollings C. Renton | Chairman, President and Chief Executive Officer, Onyx
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
George A. Scangos, PhD | President and Chief Executive Officer, Exelixis
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
CEO Leading Lights: 2007 JB&B Thought Leader Interviews
|
Henri A. Termeer | Chairman, President and Chief Executive Officer, Genzyme Corporation
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Sustaining Innovation and Growth in the Global Arena
Mike Ruettgers
|
Abstract:
At the top of every ambitious organization's agenda today-no matter its industry-is growth. In business there appears to be no Rosetta stone for understanding what it takes to sustain success. This article highlights factors that contribute to sustaining grwoth in the global arena.
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Bringing Biotechnology Health Innovations to Patients Requires a Stronger FDA
James C. Greenwood
|
Abstract:
The rapidly advancing science of biotechnology is leading us to a way of life barely imaginable just a few short years ago. But to fulfill biotechnology's promise of personalized health care and new cures and preventions for age-old diseases, we must maintain a strong innovation pipeline that helps safe and effective new therapies reach patients in a timely way. To do so it is critical to provide adequate public funding to the Food and Drug Administration (FDA). The agency's budget has not kept pace with the demands placed upon in an era of rapid biotechnological and medical innovation and it is in danger of becoming a bottleneck to innovation. The Biotechnology Industry Organization (BIO) has joined a broad coalition of patient, consumer and industry organizations to advocate for increased funding and public support for the FDA so that the agency can fulfill its mission of ensuring the safety and efficacy of new therapies and other regulated products.
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
|
Click to buy
|
The Biopharmaceutical Industry in Massachusetts-The Triple Helix in Action
Ashley J. Stevens
|
Abstract:
In 1980, Massachusetts was home to defense contractors and computer manufacturers and what Governor Michael Dukakis later called "The Massachusetts Miracle" did not bring to mind the life sciences. What economic activity there was in life sciences consisted of a largely invisible medical device industry, while the future biotechnology industry was just starting to spin-out of the laboratories of Harvard, MIT and Boston University. Yet in the space of just 25 years Massachusetts has become the leading center, worldwide, of first biotechnology research, then pharmaceutical research and most recently for the production of biopharmaceuticals. A number of its home grown biotechnology companies have developed into fully integrated biopharmaceutical and pharmaceutical companies, with substantial marketing, sales and all the necessary corporate functions The term "Triple Helix" was coined by Henry Etzkowitz in 1993 to describe the intertwining binding together academia, industry and government to create research driven high technology clusters. Nowhere is this paradigm more vividly seen in action than in the emergence of the Massachusetts biopharmaceutical mega-cluster. The Triple Helix has undergone at least three full turns in Massachusetts. This article explores some of the actions that catalyzed this phenomenon.
8 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
|
Click to buy
|
Biotech Licensing from Universities: A Maturing of Perspective
Lita Nelsen
|
Abstract:
Technology transfer from universities through invention licensing is so pervasive that we forget how recent the activity is. The Bayh-Dole Act-which allowed universities to take title to inventions arising from Federally-funded research and was the seminal event in accelerating university technology transfer-was passed in 1980, and it took more than a decade after that for most universities to establish robust licensing programs. This article addresses past and present debates related to licensing biotechnology inventions with a focus on patents in facilitating the development of and affordable access to medicines and vaccines for developing countries.
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
State Pension Funds as a Source of Capital for Investing in Economic Growth: The Massachusetts Model
Timothy Cahill
|
Abstract:
The mission of the Commonwealth of Massachusetts' pension system is to maximize the return on investment within acceptable levels of risk by broadly diversifying its investment portfolio, capitalizing on economies of scale to achieve cost-effective operations, and providing access to high quality, innovative investment management firms.
3 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Marine Bioprospecting and Sustainable Regional Development Policies
Harlyn O. Halvorson and Fernando Quezada
|
Abstract:
The promises of discovering successful drugs leads from bioactive marine molecules are yet to be realized. However the mega-diverse countries of the world continue to explore both land-based and marine bioprospecting activities as part of their overall sustainable development programs and policies. Several such countries are preparing to increase their investments in the necessary science and technology infrastructure for this purpose. In this regard the mega-diverse countries are reviewing their needs in intellectual property protection, regulatory frameworks, value chain opportunities and overall commercialization efforts.
4 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
New Technologies for Ancient Diseases
Carl B. Feldbaum
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Making the World Safe for Biotech Patents
Bruce A. Lehman
|
Abstract:
No Abstract
5 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Preserving Our Digital Heritage: The Stakes Are High
Mike Ruettgers
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
The Wake-Up Call of Corporate Governance
Stuart N. Brotman
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Cartography, History, Genomes and Intellectual Property
Juan Enriquez
|
Abstract:
No Abstract
3 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Bioterrorism: A Challenge We Cannot Decline to Meet
Carl B. Feldbaum
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Perspectives from the Street: Life after Enron in the World of Biotech
Stelios Papadopoulos
|
Abstract:
No Abstract
3 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Restoring Public Trust In Gene Therapy
Senator Edward M. Kennedy
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Special Challenges in Applying Genomics to Population Health
Gilbert S. Omenn
|
Abstract:
No Abstract
3 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
New and Daunting Responsibilities for Judges: "Doing Science" in the 21st Century
The Hon. Justice Andre M. Davis
|
Abstract:
No Abstract
3 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
In Pursuit of Patents: 21st Century Challenges
Robin JR Blatt
|
Abstract:
No Abstract
4 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Priorities for the Century of the Life Sciences
Senator Edward M. Kennedy
|
Abstract:
No Abstract
2 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
Click to buy
|
Banking Biological Collections
Robin JR Blatt
|
Abstract:
No Abstract
3 pages
©2007
by The Journal of BioLaw & Business. All Rights Reserved.
Back
to Top
|
